

**SUPPLEMENTARY MATERIAL**

	Gender/ age	Culprit drug	IR severity*	Skin tests	Pheno- type	OMZ dose regimen	OMZ doses before 1 <sup>st</sup> DS	Outcome BTR during DS	Number of DS
Cahill 2012	-/68	Oxaliplatin	Grade 3	ID-	CR	150 mg/ 2w	2	Mild	4
Ojaimi 2014	F/63	Carboplatin	Grade 3	ID+	Type 1 (IgE)	300 mg/ 2w	3	No	5
Hong 2018	3 cases	Platin/taxane/ mAb	-	-	Type 1 (IgE)	300 mg/ 4w	1	Mild	-
De las Vecillas 2019	F/60	Oxaliplatin	Grade 3	ID+	Type 1 (IgE)	600 mg/ 300 mg 2 w and 1 day before DS	2	Mild only at 1 <sup>st</sup>	5
Sánchez Morillas 2019	F/57 F/61	Carboplatin	Grade 3 Grade 3	ID+	Type 1 (IgE)	300 mg initial 150 mg/ 2w	2	No Mild	6 4
Penella 2020	M/57	Oxaliplatin	Grade 3	ID+	Type 1 (IgE)	300 mg/ 2w	1	Mild only at 1 <sup>st</sup>	5
Oude 2020	F/57	Carboplatin	Grade 2	ID+	Type 1 (IgE)	300 mg/ 2w	1	No	4
Vultaggio 2021	F/60 F/60 F/76	Carboplatin	Grade 3 Grade 2 Grade 2	ID+ ID+ ID-**	Type 1 (IgE)	600 mg 15 and 2 days before 1 <sup>st</sup> DS Then 2 days before each cycle	2	No No No	4 4 4

**Supplementary Table:** Reported cases in the literature with adjuvant use of omalizumab for chemotherapeutics desensitization. BTR: breakthrough reaction; CR: cytokine release; DS: desensitization; F: female; ID: intradermoreaction; IR: initial reaction; mAb: monoclonal antibody; M: male; OMZ: omalizumab; W: week.\*according to Brown scale; \*\*performed 6 years after initial reaction.